Clinical and patient‐reported outcomes of SPARE – a randomised feasibility study of selective bladder preservation versus radical cystectomy

To test the feasibility of a randomised trial in muscle‐invasive bladder cancer (MIBC) and compare outcomes in patients who receive neoadjuvant chemotherapy followed by radical cystectomy (RC) or selective bladder preservation (SBP), where definitive treatment [RC or radiotherapy (RT)] is determined by response to chemotherapy.

• Publication year

  2017

• Venue

  BJU International

• Publication date

  2017-05-29

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/bju.13900PMID 28453896PMCID 5655733
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Bladder cancer

  2016cited by this paper
• Selective organ preservation with neo-adjuvant chemotherapy for the treatment of muscle invasive transitional cell carcinoma of the bladder

  2016influential reference
• Preliminary Comparative Effectiveness of Robotic Versus Open Radical Cystectomy in Elderly Patients

  2016cited by this paper
• A Single-centre Early Phase Randomised Controlled Three-arm Trial of Open, Robotic, and Laparoscopic Radical Cystectomy (CORAL).

  2016cited by this paper
• Selective organ preservation with neo-adjuvant chemotherapy for the treatment of muscle invasive transitional cell carcinoma of the bladder

  2015cited by this paper
• Critical analysis of bladder sparing with trimodal therapy in muscle-invasive bladder cancer: a systematic review.

  2014cited by this paper
• Curative therapy for bladder cancer in routine clinical practice: a population-based outcomes study.

  2014cited by this paper
• Normal tissue sparing in a phase II trial on daily adaptive plan selection in radiotherapy for urinary bladder cancer

  2014cited by this paper
• The outcome of a multi-centre feasibility study of online adaptive radiotherapy for muscle-invasive bladder cancer TROG 10.01 BOLART.

  2014cited by this paper
• Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy: a pooled analysis of Radiation Therapy Oncology Group protocols 8802, 8903, 9506, 9706, 9906, and 0233.

  2014cited by this paper
• Clinical implementation of adaptive hypofractionated bladder radiotherapy for improvement in normal tissue irradiation.

  2013cited by this paper
• Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer.

  2012cited by this paper
• Expression of TIP60 (tat‐interactive protein) and MRE11 (meiotic recombination 11 homolog) predict treatment‐specific outcome of localised invasive bladder cancer

  2012cited by this paper
• Current Strategies to Enhance Recovery following Radical Cystectomy: Single Centre Initial Experience

  2012cited by this paper
• The Patient Deficit Model Overturned: a qualitative study of patients' perceptions of invitation to participate in a randomized controlled trial comparing selective bladder preservation against surgery in muscle invasive bladder cancer (SPARE, CRUK/07/011)

  2012cited by this paper
• Bladder preservation for localized muscle-invasive bladder cancer: the survival impact of local utilization rates of definitive radiotherapy.

  2012cited by this paper
• International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial.

  2011cited by this paper
• Key issues in recruitment to randomised controlled trials with very different interventions: a qualitative investigation of recruitment to the SPARE trial (CRUK/07/011)

  2011cited by this paper
• MRE11 expression is predictive of cause-specific survival following radical radiotherapy for muscle-invasive bladder cancer.

  2010cited by this paper
• A 10-year retrospective review of a nonrandomized cohort of 458 patients undergoing radical radiotherapy or cystectomy in Yorkshire, UK.

  2010cited by this paper
• Differential complication rates following radical cystectomy in the irradiated and nonirradiated pelvis.

  2010cited by this paper
• LIFE AND DEATH OF SPARE (SELECTIVE BLADDER PRESERVATION AGAINST RADICAL EXCISION): REFLECTIONS ON WHY THE SPARE TRIAL CLOSED

  2010cited by this paper
• Similar treatment outcomes for radical cystectomy and radical radiotherapy in invasive bladder cancer treated at a United Kingdom specialist treatment center.

  2008cited by this paper
• The surgical management of muscle invasive bladder cancer: a contemporary review.

  2005cited by this paper
• Selective bladder preservation by trimodality therapy for patients with muscularis propria-invasive bladder cancer and who are cystectomy candidates--the Massachusetts General Hospital and Radiation Therapy Oncology Group experiences.

  2005cited by this paper
• Neoadjuvant Chemotherapy in Invasive Bladder Cancer: Update of a Systematic Review and Meta-Analysis of Individual Patient Data: Advanced Bladder Cancer (ABC) Meta-analysis Collaboration

  2005cited by this paper
• Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration.

  2005cited by this paper
• Prospective quality-of-life assessment in patients receiving concurrent gemcitabine and radiotherapy as a bladder preservation strategy.

  2004cited by this paper
• Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer.

  2003cited by this paper
• Muscle-invasive transitional cell carcinoma of the urinary bladder: a population-based study of patterns of care and prognostic factors.

  2001cited by this paper
• The ileal neobladder: complications and functional results in 363 patients after 11 years of followup.

  1999cited by this paper
• Neo-adjuvant chemotherapy and bladder preservation in locally advanced transitional cell carcinoma of the bladder.

  1999influential reference
• Neo-adjuvant chemotherapy and bladder preservation in locally advanced transitional cell carcinoma of the bladder.

  1999cited by this paper
• Bladder cancer.

  1998cited by this paper
• The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology.

  1993cited by this paper
• Bladder cancer definitive radiation therapy of muscle‐invasive bladder cancer: A retrospective analysis of 317 patients

  1993cited by this paper
• The prognostic value of the pathological response to combination chemotherapy before cystectomy in patients with invasive bladder cancer. European Organization for Research on Treatment of Cancer--Genitourinary Group.

  1992cited by this paper

• Advances in immunotherapy for bladder cancer and clinical practice of next-generation sequencing

  2026cites this paper
• Spierinvasieve blaaskanker in Nederland: oncologische uitkomsten na radicale cystectomie en blaassparende therapie

  2026cites this paper
• The changing landscape of urothelial carcinoma: on the edge of a paradigm shift.

  2026cites this paper
• Muscle-Invasive Bladder Cancer: A Watershed Moment.

  2025cites this paper
• Recent Advances and Future Directions in Bladder Preservation Therapy for Muscle‐Invasive Bladder Cancer

  2025cites this paper
• Comparison of long-term survival for muscle-invasive bladder cancer patients who underwent bladder preservation therapy and radical cystectomy: A systematic review and meta-analysis

  2025cites this paper
• Cost-Effectiveness of Trimodal Therapy and Radical Cystectomy for Muscle-Invasive Bladder Cancer

  2025cites this paper
• Trimodal Treatment vs Radical Cystectomy for Muscle-invasive Bladder Cancer: the Neglected Impact of Informative Censoring. A Systematic Review and Meta-analysis.

  2025cites this paper
• The importance of maximal TURBT in trimodality therapy for muscle-invasive bladder cancer (MIBC)

  2025cites this paper
• Cancer‐Specific Survival of Trimodal Therapy Versus Radical Cystectomy in T2N0M0 Non‐Urothelial Bladder Cancer

  2025cites this paper
• Characterization of treatment patterns and outcomes in muscle-invasive bladder cancer patients in Sweden.

  2025cites this paper
• Real-World Study of Short-Term and Long-Term Clinical Outcomes With Radical Cystectomy for Bladder Cancer in the United States

  2025cites this paper
• Urothelial carcinoma: Perioperative considerations from top to bottom

  2025cites this paper
• Combining Radiotherapy with Immune Checkpoint Inhibitors for the Management of Muscle-Invasive Bladder Cancer: A Comprehensive Systematic Review from the Y-ECI ROSC EORTC group.

  2025cites this paper
• Oncological outcomes after non-surgical management versus radical cystectomy in non-organ-confined non-urothelial bladder cancer

  2025cites this paper
• Optimizing treatment selection: outcomes of radical cystectomy in patients eligible for trimodal therapy

  2025cites this paper
• Real-World Economic Burden and Healthcare Resource Utilization of Radical Cystectomy and Trimodal Therapy for Bladder Cancer in the United States.

  2025cites this paper
• Survival outcomes and temporal trends of non-surgical management versus radical cystectomy in non-organ-confined urothelial bladder cancer.

  2025cites this paper
• Trimodality therapy versus radical cystectomy for muscle-invasive bladder cancer: A systematic review and meta-analysis.

  2025cites this paper
• Bladder-Sparing Approaches in Muscle Invasive Bladder Cancer

  2025cites this paper
• 2025 Canadian Urological Association Expert Report: Muscle-invasive bladder cancer.

  2025cites this paper
• A nomogram for predicting lymph node metastases in nonmetastatic muscle-invasive bladder cancer: a SEER-based investigation.

  2025cites this paper
• Current status and advances in bladder-sparing treatment for non-metastatic muscle-invasive bladder cancer

  2025cites this paper
• The Future of Bladder Preservation for Muscle-invasive Bladder Cancer.

  2025cites this paper
• Comparison of the overall survival of different treatment methods in patients with Muscle-invasive bladder cancer: A retrospective study

  2024cites this paper
• Survival after trimodal therapy in octogenarians with organ‐confined urothelial bladder cancer

  2024cites this paper
• Bladder preservation alternatives in non-metastatic muscle-invasive bladder tumor: A systematic review and meta-analysis

  2024cites this paper
• Trimodal Therapy in the Treatment of Muscle-Invasive Bladder Cancer

  2024cites this paper
• Recommandations françaises du Comité de cancérologie de l’AFU – Actualisation 2024–2026 : tumeurs de la vessie infiltrant le muscle (TVIM)

  2024cites this paper
• French AFU Cancer Committee Guidelines - Update 2024-2026: Muscle-invasive bladder cancer (MIBC).

  2024cites this paper
• Trimodality Therapy Versus Radical Cystectomy for Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis of Matched Cohort Studies.

  2024cites this paper
• Eligibility and Endpoints for Clinical Trials in Trimodality Therapy for Bladder Cancer

  2024cites this paper
• From the Editor September 2024: The Spectrum of Clinical Trial Reports

  2024cites this paper
• News and prospects on radiotherapy for bladder cancer: Is trimodal therapy becoming the gold standard?

  2024cites this paper
• Editorial: Bladder preservation options for bladder cancer

  2024cites this paper
• Radical cystectomy versus trimodal therapy for muscle-invasive bladder cancer: Analysis of an other-cause mortality matched cohort.

  2024cites this paper
• Advancements in Urothelial Cancer Care: Optimizing Treatment for Your Patient.

  2024cites this paper
• Efficiency of bladder-sparing strategies for bladder cancer: an umbrella review

  2024cites this paper
• Muscle-invasive bladder cancer in elderly and frail people: Is hypofractionated radiotherapy a feasible approach when no other local options are available?

  2024cites this paper
• Organ preservation in muscle-invasive urothelial bladder cancer

  2024cites this paper
• Beyond surgery: bladder preservation and the role of systemic treatment in localised muscle-invasive bladder cancer

  2024cites this paper
• Is trimodal therapy the current standard for muscle-invasive bladder cancer?

  2024cites this paper
• Health-related quality of life after curative treatment for muscle-invasive bladder cancer

  2023cites this paper
• Bladder Preservation for Muscle-Invasive Bladder Cancer With Variant Histology.

  2023cites this paper
• Comparing trimodal therapy with radical cystectomy in muscle-invasive bladder cancer: an updated meta-analysis

  2023cites this paper
• Reply to W. He et al.

  2023cites this paper
• Quality of life after definitive treatment for bladder cancer: a systematic review and meta-analysis.

  2023cites this paper
• Selective multimodal bladder-sparing therapy for muscle-invasive bladder cancer: the present and the future

  2023cites this paper
• Bladder-sparing treatment for muscle-invasive bladder carcinoma using immune checkpoint inhibitors.

  2023cites this paper
• Induction therapy with ipilimumab and nivolumab followed by consolidative chemoradiation as organ-sparing treatment in urothelial bladder cancer: study protocol of the INDIBLADE trial

  2023cites this paper
• Radical Cystectomy Versus Bladder-Preserving Therapy in Muscle-Invasive Bladder Cancer Patients After Nephroureterectomy for Upper Tract Urothelial Carcinoma: A Multicenter Retrospective Analysis

  2023cites this paper
• Disease-free survival of patients with muscle invasive bladder cancer treated with radical cystectomy versus bladder preserving therapy: a nationwide study.

  2023cites this paper
• Bladder-Sparing Treatment With Radical Dose Radiotherapy Is an Effective Alternative to Radical Cystectomy in Patients With Clinically Node-Positive Nonmetastatic Bladder Cancer

  2023cites this paper
• Bladder-sparing strategies in patients with clinically localized muscle-invasive bladder cancer

  2023cites this paper
• Predictors of trimodality therapy in patients with muscle-invasive bladder cancer and effect on survival

  2023cites this paper
• Trimodality therapy in the modern era for management of bladder cancer

  2023cites this paper
• Myths About Bladder Preservation in Muscle-Invasive Bladder Cancer.

  2023cites this paper
• Radical cystectomy versus trimodality therapy for muscle-invasive bladder cancer: a multi-institutional propensity score matched and weighted analysis.

  2023cites this paper
• Bladder preservation by neoadjuvant chemotherapy followed by concurrent chemoradiation for muscle-invasive bladder cancer

  2023cites this paper
• Radiation-based Therapy for Muscle-invasive Bladder Cancer: Contemporary Outcomes Across Tertiary Centers.

  2023cites this paper
• Combined Modality Bladder-Sparing Therapy for Muscle-Invasive Bladder Cancer: How (Should) We Do It? A Narrative Review

  2023cites this paper
• The Role of Immunotherapy as Bladder-Sparing Solution for Muscle-Invasive and Non-muscle-Invasive Bladder Cancer: Current Status and Future Perspectives

  2022cites this paper
• Radical cystectomy versus trimodality therapy for muscle-invasive urothelial carcinoma of the bladder.

  2022cites this paper
• Trimodal therapy vs. radical cystectomy for muscle-invasive bladder cancer: A Canadian cost-effectiveness analysis.

  2022cites this paper
• Bladder-Sparing Approaches to Treatment of Muscle-Invasive Bladder Cancer

  2022cites this paper
• A Multicenter Retrospective Cohort Series of Muscle-invasive Bladder Cancer Patients Treated with Definitive Concurrent Chemoradiotherapy in Daily Practice

  2022cites this paper
• Biomarkers in muscle invasive bladder cancer.

  2022cites this paper
• Disease Management of Clinical Complete Responders to Neoadjuvant Chemotherapy of Muscle-Invasive Bladder Cancer: A Review of Literature

  2022cites this paper
• Clinical Trial Considerations for Bladder Preservation in Muscle-Invasive Bladder Cancer

  2022cites this paper
• Comparing Long-Term Survival Outcomes for Muscle-Invasive Bladder Cancer Patients Who Underwent with Radical Cystectomy and Bladder-Sparing Trimodality Therapy: A Multicentre Cohort Analysis

  2022cites this paper
• [Bladder-sparing trimodal therapy for muscle invasive bladder cancer].

  2022cites this paper
• Guideline on trimodal therapy of bladder cancer (Nevskiy consensus 2021)

  2022cites this paper
• Dynamic changes of quality of life in muscle-invasive bladder cancer survivors

  2022cites this paper
• Urothelkarzinom der Harnblase: Radiotherapeutische Verfahren

  2022cites this paper
• Correlates of refusal of radical cystectomy in patients with muscle-invasive bladder cancer.

  2021cites this paper
• Trimodal therapy vs. radical cystectomy for muscle-invasive bladder cancer: A Markov microsimulation model.

  2021cites this paper
• Trimodal Therapy

  2021cites this paper
• Recommendations for planning and delivery of radical radiotherapy for localized urothelial carcinoma of the bladder.

  2021cites this paper
• Abbreviated Concurrent Chemo-Radiotherapy in Node Negative Muscle-Invasive Bladder Cancer

  2021cites this paper
• A phase II study of neoadjuvant chemotherapy followed by organ preservation in patients with muscle-invasive bladder cancer

  2021cites this paper
• Quality of Life following Chemoradiotherapy for Localized Muscle Invasive Bladder Carcinoma: A Systematic Review

  2021influential citation
• Surgical clinical trials with non-inferiority design: a cross-sectional bibliometric analysis

  2021cites this paper
• A practical approach to bladder preservation with hypofractionated radiotherapy for localised muscle-invasive bladder cancer

  2021cites this paper
• Hypofractionation: less is more?

  2021cites this paper
• A 25-year perspective on advances in an understanding of the biology, evaluation, treatment and future directions/challenges of urothelial cancer.

  2021cites this paper
• Re: Radical Cystectomy Against Intravesical BCG for High-risk High-grade Nonmuscle Invasive Bladder Cancer: Results from the Randomized Controlled BRAVO-feasibility Study.

  2021cites this paper
• Bladder cancer: shedding light on the most promising investigational drugs in clinical trials

  2021cites this paper
• A Systematic Review on Bladder Preservation Strategies and MIBC

  2021cites this paper
• Bladder preservation versus radical cystectomy in transitional cell carcinoma and squamous cell carcinoma muscle invasive bladder cancer

  2021influential citation
• Long-term outcomes after bladder-preserving tri-modality therapy for patients with muscle-invasive bladder cancer

  2021influential citation
• Bladder Radiotherapy: Is Cinderella Ready for the Ball?

  2021cites this paper
• Bladder Preservation With Radiotherapy: The Patient Perspective.

  2021cites this paper
• Patient-Reported Outcomes and Health-Related Quality of Life Following Radiotherapy for Bladder Cancer.

  2021cites this paper
• Management of Localized Muscle-Invasive Bladder Cancer from a Multidisciplinary Perspective: Current Position of the Spanish Oncology Genitourinary (SOGUG) Working Group

  2021cites this paper
• Overcoming the Chasm Between Evidence and Routine Practice for Bladder Cancer; Just a Quixotic Notion?

  2021cites this paper
• Long term outcomes of radical radiotherapy with hypoxia modification with biomarker discovery for stratification: Ten year update of the BCON (Bladder CarbOgen Nicotinamide) phase III randomised trial (ISRCTN45938399).

  2021cites this paper
• Neoadjuvant Chemotherapy–Guided Bladder-Sparing Treatment for Muscle-Invasive Bladder Cancer: Results of a Pilot Phase II Study

  2021cites this paper
• Treatment of muscle-invasive bladder cancer in patients without comorbidities and fit for surgery: trimodality therapy vs radical cystectomy. Development of GRADE (Grades of Recommendation, Assessment, Development and Evaluation) Recommendation by the Italian Association of Radiotherapy and Clinical

  2021cites this paper
• Failing to Close the Gap between Evidence and Clinical Practice in Radical Bladder Cancer Radiotherapy: A Critical Unmet Need.

  2021cites this paper
• The impact of the COVID-19 pandemic on radiotherapy services in England, UK: a population-based study

  2021cites this paper